<DOC>
	<DOCNO>NCT01477853</DOCNO>
	<brief_summary>This two-phase study examine 16 week treatment sitagliptin combination atorvastatin reduce hemoglobin A1C ( A1C ) low density lipoprotein cholesterol ( LDL-C ) baseline atorvastatin alone sitagliptin alone , respectively . Following single-blind placebo run-in period , participant randomize one three treatment arm ( sitagliptin monotherapy , atorvastatin monotherapy , sitagliptin plus atorvastatin ) 16 week ( Phase A ) . During Phase B study ( Weeks 16 54 ) , participant receive either sitagliptin plus atorvastatin glimepiride plus atorvastatin . The primary hypothesis 16 week treatment , sitagliptin combination atorvastatin reduce A1C baseline atorvastatin alone , atorvastatin combination sitagliptin lower LDL-C baseline sitagliptin alone .</brief_summary>
	<brief_title>A Study Co-administration Sitagliptin Atorvastatin Inadequately Controlled Type 2 Diabetes Mellitus ( MK-0431E-211 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>type 2 diabetes mellitus male , female highly unlikely conceive currently monotherapy metformin ( least 1500 mg/day ) least 8 week statin therapy lipidlowering agent least 6 week history type 1 diabetes mellitus , ketoacidosis possibly type 1 diabetes ever take dipeptidyl peptidase IV inhibitor ( sitagliptin , vildagliptin , alogliptin , saxagliptin ) glucagonlike peptide1 mimetic ( exenatide liraglutide ) , require insulin therapy within 12 week prior sign inform consent peroxisome proliferatoractivated receptor gamma agonist within prior 12 week treat statin lipidlowering agent , include counter supplement fish oil within 6 week intend consume least 1.2 liter grapefruit juice per day course study likely require treatment 14 consecutive day , repeat course corticosteroid weight loss program maintenance phase start weight loss medication ( orlistat sibutramine ) within prior 8 week undergone surgical procedure within prior 4 week history myopathy rhabdomyolysis statin . cardiovascular disease New York Heart Association ( NYHA ) Class III IV congestive heart failure , inadequately control hypertension , medical history active liver disease , chronic progressive neuromuscular disorder , human immunodeficiency virus ( HIV ) positive , clinically significant hematological disorder , uncontrolled endocrine metabolic disease know influence glycemic control serum lipids/lipoproteins , untreated hyperthyroidism currently treatment hyperthyroidism history malignancy within 5 year , except adequately treat basal cell squamous cell skin cancer situ cervical cancer pregnant breastfeeding , intend become pregnant donate egg within project duration study poststudy followup period use recreational illicit drug recent history ( within last year ) drug abuse increase alcohol consumption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>